Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Pfizer 3Q11

Revenues up 7%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 3Q11

3Q Revenues: $17.2 billion  (+7%)

3Q Earnings: $3.7 billion (earnings were $866 million 3Q10)

YTD Revenues: $50.7 billion (+2%)

YTD Earnings: $8.6 billion (+60%)

Comments: Lipitor sales were $2.6 billion (+3%). Prevnar/Prevenar 13 revenues were up 37% to $1.0 billion. Celebrex sales were $643 million (+11%). Lyrica sales were $961 million (+27%). Pristiq sales were up 24% to $146 million. Legacy King products accounted for $119 million in the quarter. Biopharmaceutical products accounted for $14.7 billion (+6%). U.S. revenues were $6.9 billion, down 3%. International revenues were $10.3 billion, up 15%. Foreign exchange accounted for $951 million, or 6% of growth in the quarter.  Results were favorably impacted by a $1.3 billion gain on the sale of Capsugel in 3Q11, as well as the non-recurrence of impairment charges of $1.5 billion related to certain assets acquired with the Wyeth acquisition and a $701 million charge for asbestos litigation related to subsidiary, Quigley Company, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters